Sigma-1 receptors: Potential targets for the treatment of substance abuse

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 902-919

  Robson, Matthew J ^a   Noorbakhsh, Bahar ^a   Seminerio, Michael J ^a   Matsumoto, Rae R ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Addiction; Cocaine; Drug abuse; Ethanol; Methamphetamine; Nicotine; Opioid; Sigma receptor

Indexed keywords

1 (4 FLUOROPHENYL) 4 [4 (5 FLUOROPYRIMIDIN 2 YL)PIPERAZIN 1 YL]BUTAN 1 OL; 1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 6 [6 (4 HYDROXY 1 PIPERIDINYL)HEXYLOXY] 3 METHYLFLAVONE; 6 [6 (4 HYDROXYPIPERIDINYL)HEXYLOXY] 3 METHYLFLAVONE; ALCOHOL; ALPHA (4 FLUOROPHENYL) 4 (5 FLUORO 2 PYRIMIDINYL) 1 PIPERAZINEBUTANOL; AMFEBUTAMONE; BD 0147; BD 1063; COCAINE; CUTAMESINE; DONEPEZIL; DOPAMINE TRANSPORTER; FLUVOXAMINE; HALOPERIDOL; IGMESINE; LR 132; MESSENGER RNA; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID; NICOTINE; PENTAZOCINE; PRASTERONE; PROTEIN C FOS; REACTIVE OXYGEN METABOLITE; SEROTONIN TRANSPORTER; SERTRALINE; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; TRANSCRIPTION FACTOR DELTA FOSB; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR FRA 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADDICTION; ALCOHOLISM; ARTICLE; COGNITIVE DEFECT; CONVULSION; DRUG DEPENDENCE; DRUG OVERDOSE; GENE CONTROL; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL PLASTICITY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING CESSATION; STIMULUS RESPONSE; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; UNITED STATES; UPREGULATION; WISTAR RAT;

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; RECEPTORS, SIGMA; SUBSTANCE-RELATED DISORDERS;

EID: 84857128284     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436601     Document Type: Article

References (181)

1. Policy NDC. The economic costs of drug abuse in the United States 1992-2002. Washington, DC: Executive Office of the President 2004; Publication No: 207303.
2. Rich JD, Wakeman SE, Dickman SL. Medicine and the epidemic of incarceration in the United States. N Engl J Med 2011; 364: 2081-3.
3. Alonso G, Phan V, Guillemain I, et al. Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. Neuroscience 2000; 97: 155-70.
4. Phan VL, Alonso G, Sandillon F, Privat A, Maurice T. Therapeutic potentials of sigma1 receptor ligands against cognitive deficits in aging. Soc Neurosci Abstr 2000; 26: 2172.
5. Samovilova NN, Vinogradov VA. Subcellular distribution of (+)-[3H]SKF 10,047 binding sites in rat liver. Eur J Pharmacol 1992; 225: 69-74.
6. Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 1994; 269: 1300-9.
7. Roman F, Pascaud X, Vauche D, Junien JL. Evidence for a nonopioid sigma binding site in the guinea-pig myenteric plexus. Life Sci 1988; 42: 2217-22.
8. Roman F, Pascaud X, Chomette G, Bueno L, Junien JL. Autoradiographic localization of sigma opioid receptors in the gastrointestinal tract of the guinea pig. Gastroenterology 1989; 97: 76-82.
9. Jbilo O, Vidal H, Paul R, et al. Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem 1997; 272: 27107-15.
10. Hanner M, Moebius FF, Flandorfer A, et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A 1996; 93: 8072-7.
11. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ERmitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007; 131: 596-610.
12. Sharkey J, Glen KA, Wolfe S, Kuhar MJ. Cocaine binding at sigma receptors. Eur J Pharmacol 1988; 149: 171-4.
13. Liu Y, Chen GD, Lerner MR, Brackett DJ, Matsumoto RR. Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J Pharmacol Exp Ther 2005; 314: 770-9.
14. Matsumoto RR, Hewett KL, Pouw B, et al. Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology 2001; 41: 878-86.
15. de Costa BR, Bowen WD, Hellewell SB, et al. Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett 1989; 251: 53-8.
16. Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JF. 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigmatype receptors for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci U S A 1986; 83: 8784-8.
17. de Costa BR, Radesca L, Di Paolo L, Bowen WD. Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor. J Med Chem 1992; 35: 38-47.
18. Gonzalez-Alvear GM, Werling LL. Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther 1994; 271: 212-9.
19. Gonzalez-Alvear GM, Werling LL. Sigma1 Receptors in rat striatum regulate NMDA-stimulated [3H]dopamine release via a presynaptic mechanism. Eur J Pharmacol 1995; 294: 713-9.
20. Gudelsky GA. Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur J Pharmacol 1995; 286: 223-8.
21. Weatherspoon JK, Gonzalez-Alvear GM, Frank AR, Werling LL. Regulation of [3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophr Res 1996; 21: 51-62.
22. Gonzalez GM, Werling LL. Release of [3H]dopamine from guinea pig striatal slices is modulated by sigma1 receptor agonists. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 455-61.
23. Kobayashi T, Matsuno K, Murai M, Mita S. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem Res 1997; 22: 1105-9.
24. Su TP, Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003; 10: 2073-80.
25. Liu Y, Matsumoto RR. Alterations in fos-related antigen 2 and sigma1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: time course and regional distribution studies. J Pharmacol Exp Ther 2008; 327: 187-95.
26. Hayashi T, Su TP. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci 2005; 77: 1612-24.
27. Yang S, Alkayed NJ, Hurn PD, Kirsch JR. Cyclic adenosine monophosphate response element-binding protein phosphorylation and neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP). Anesth Analg 2009; 108: 964-70.
28. Tilley MR, O'Neill B, Han DD, Gu HH. Cocaine does not produce reward in absence of dopamine transporter inhibition. Neuroreport 2009; 20: 9-12.
29. NIDA Research Report Cocaine. Bethesda, MD: NIDA; NIH Pub Number 10-4166 [revised 09/2010; cited 10/22/2011]. Available from: http://drugabuse.gov/PDF/RRCocaine.pdf.
30. NIDA Cocaine Infofacts. Bethesda, MD: NIDA; [revised 03/2010; cited 10/22/2011]. Available from: http://drugabuse.gov/infofacts/cocaine.html.
31. Hicks MJ, De BP, Rosenberg JB, et al. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 2011; 19: 612-9.
32. Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR. Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002; 26: 499-527.
33. Matsumoto RR, McCracken KA, Pouw B, et al. N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice. Eur J Pharmacol 2001; 411: 261-73.
34. Ushijima I, Kobayashi T, Suetsugi M, Watanabe K, Yamada M, Yamaguchi K. Cocaine: evidence for NMDA-, beta-carboline-and dopaminergic-mediated seizures in mice. Brain Res 1998; 797: 347-50.
35. Witkin JM, Terry P, Menkel M, et al. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther 1993; 266: 473-82.
36. Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 2001; 419: 163-74.
37. Matsumoto RR, Li SM, Katz JL, Fantegrossi WE, Coop A. Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug Alcohol Depend 2011; 118: 40-7.
38. Xu YT, Kaushal N, Shaikh J, et al. A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice. J Pharmacol Exp Ther 2010; 333: 491-500.
39. McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur J Pharmacol 1999; 370: 225-32.
40. Matsumoto RR, Potelleret FH, Mack A, Pouw B, Zhang Y, Bowen WD. Structure-activity comparison of YZ-069, a novel sigma ligand, and four analogs in receptor binding and behavioral studies. Pharmacol Biochem Behav 2004; 77: 775-81.
41. Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002; 42: 1043-55.
42. Romieu P, Martin-Fardon R, Maurice T. Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. Neuroreport 2000; 11: 2885-8.
43. Romieu P, Phan VL, Martin-Fardon R, Maurice T. Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002; 26: 444-55.
44. Hiranita T, Soto PL, Tanda G, Katz JL. Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine. J Pharmacol Exp Ther 2010; 332: 515-24.
45. Chen JC, Chen PC, Chiang YC. Molecular mechanisms of psychostimulant addiction. Chang Gung Med J 2009; 32: 148-54.
46. Young ST, Porrino LJ, Iadarola MJ. Cocaine induces striatal c-fosimmunoreactive proteins via dopaminergic D1 receptors. Proc Natl Acad Sci U S A 1991; 88: 1291-5.
47. Hope BT. Cocaine and the AP-1 transcription factor complex. Ann N Y Acad Sci 1998; 844: 1-6.
48. Navarro G, Moreno E, Aymerich M, et al. Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc Natl Acad Sci U S A 2010; 107: 18676-81.
49. Anderson SM, Pierce RC. Cocaine-induced alterations in dopamine receptor signaling: implications for reinforcement and reinstatement. Pharmacol Ther 2005; 106: 389-403.
50. Xu M, Hu XT, Cooper DC, Moratalla R, Graybiel AM, White FJ, Tonegawa S. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 1994; 79: 945-55.
51. Bertran-Gonzalez J, Bosch C, Maroteaux M, et al. Opposing patterns of signaling activation in dopamine D1 and D2 receptorexpressing striatal neurons in response to cocaine and haloperidol. J Neurosci 2008; 28: 5671-85.
52. Kong MM, Fan T, Varghese G, O'Dowd B F, George SR. Agonistinduced cell surface trafficking of an intracellularly sequestered D1 dopamine receptor homo-oligomer. Mol Pharmacol 2006; 70: 78-89.
53. Lu L, Koya E, Zhai H, Hope BT, Shaham Y. Role of ERK in cocaine addiction. Trends Neurosci 2006; 29: 695-703.
54. Zhang L, Looney D, Taub D, et al. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998; 4: 619-26.
55. Fiala M, Eshleman AJ, Cashman J, et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol 2005; 11: 281-91.
56. Fiala M, Gan XH, Zhang L, et al. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis? Adv Exp Med Biol 1998; 437: 199-205.
57. Yao H, Yang Y, Kim KJ, et al. Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood 2010; 115: 4951-62.
58. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 2006; 26: 1098-106.
59. Yao H, Duan M, Buch S. Cocaine-mediated induction of plateletderived growth factor: implication for increased vascular permeability. Blood 2011; 117: 2538-47.
60. Gan X, Zhang L, Berger O, et al. Cocaine enhances brain endothelial adhesion molecules and leukocyte migration. Clin Immunol 1999; 91: 68-76.
61. Yao H, Kim K, Duan M, et al. Cocaine hijacks {sigma}1 receptor to initiate induction of activated leukocyte cell adhesion molecule: implication for increased monocyte adhesion and migration in the CNS. J Neurosci 2011; 31: 5942-5955.
62. Masedunskas A, King JA, Tan F, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett 2006; 580: 2637-45.
63. Ujike H, Okumura K, Zushi Y, Akiyama K, Otsuki S. Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment. Eur J Pharmacol 1992; 211: 323-8.
64. Nguyen EC, McCracken KA, Liu Y, Pouw B, Matsumoto RR. Involvement of sigma (σ) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology 2005; 49: 638-45.
65. Matsumoto RR, Shaikh J, Wilson LL, Vedam S, Coop A. Attenuation of methamphetamine-induced effects through the antagonism of sigma (σ) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol 2008; 18: 871-81.
66. Basianetto S, Roquier L, Perrault G, Sanger DJ. DTG-induced circling behaviour in rats may involve the interaction between sigma sites and nigro-striatal dopaminergic pathways. Neuropharmacology 1995; 34: 281-287.
67. Booth RG, Baldessarini RJ. (+)-6,7-benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum tissue. Brain Res 1991; 557: 349-52.
68. Weiser SD, Patrick SL, Mascarella SW, et al. Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of sigma receptor ligands. Eur J Pharmacol 1995; 275: 1-7.
69. Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010; 31: 557-66.
70. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009; 323: 934-7.
71. Rodvelt KR, Oelrichs CE, Blount LR, et al. The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine. Drug Alcohol Depend 2011; 116: 203-10.
72. Xu X, Domino EF. Cross-sensitization between phencyclidine and (-) but not (+) pentazocine. Pharmacol Biochem Behav 1997; 56: 205-10.
73. Okuyama S, Imagawa Y, Tomisawa K. Behavioral evidence for modulation by sigma ligands of (+)MK-801-induced hyperlocomotion in monoamine-depleted mice. Neuropharmacology 1996; 35: 467-74.
74. Rodvelt KR, Lever SZ, Lever JR, Blount LR, Fan KH, Miller DK. SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus. Pharmacol Biochem Behav 2011; 97: 676-82.
75. Kaushal N, McCurdy CR, Matsumoto RR. SN79 attenuates the neurotoxic effects of methamphetamine: in vivo and in vitro studies. Society for Neuroscience Abstract 2011; 367.04. Available from: http://www.sfn.org/am2011/pdf/prelim/MON_Poster_AM_v2.pdf.
76. Seminerio MJ, Kaushal N, Shaikh J, Huber JD, Coop A, Matsumoto RR. Sigma (σ) receptor ligand, AC927 (Nphenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. Pharmacol Biochem Behav 2011; 98: 12-20.
77. Bowyer JF, Davies DL, Schmued L, et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994; 268: 1571-80.
78. Itzhak Y. Repeated methamphetamine-treatment alters brain sigma receptors. Eur J Pharmacol 1993; 230: 243-4.
79. Hayashi T, Justinova Z, Hayashi E, et al. Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J Pharmacol Exp Ther 2010; 332: 1054-63.
80. Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, Su TP. Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology (Berl) 2004; 175: 68-75.
81. Takahashi S, Miwa T, Horikomi K. Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats. Neurosci Lett 2000; 289: 21-4.
82. Kalivas PW, Nakamura M. Neural systems for behavioral activation and reward. Curr Opin Neurobiol 1999; 9: 223-7.
83. Cadet JL, Krasnova IN, Jayanthi S, Lyles J. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 2007; 11: 183-202.
84. Itzhak Y, Achat-Mendes C. Methamphetamine and MDMA (ecstasy) neurotoxicity: 'of mice and men'. IUBMB Life 2004; 56: 249-55.
85. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev 2009; 60: 379-407.
86. Sekine Y, Ouchi Y, Takei N, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 2006; 63: 90-100.
87. Volkow ND, Chang L, Wang GJF et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 2001; 21: 9414-8.
88. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-82.
89. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 1998; 18: 8417-22.
90. Terleckyj I, Sonsalla PK. The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. J Pharmacol Exp Ther 1994; 269: 44-50.
91. Cadet JL, Jayanthi S, Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 2003; 17: 1775-88.
92. McCambridge J, McAlaney J, Rowe R. Adult consequences of late adolescent alcohol consumption: a systematic review of cohort studies. PLoS Med 2011; 8: e1000413. Available from: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000413.
93. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373: 2223-33.
94. Harwood HJ, Fountain D, Livermore G. Economic costs of alcohol abuse and alcoholism. Recent Dev Alcohol 1998; 14: 307-30.
95. Harwood HJ, Fountain D, Fountain G. Economic cost of alcohol and drug abuse in the United States 1992: a report. Addiction 1999; 94: 631-5.
96. Soyka M, Rosner S. Emerging drugs to treat alcoholism. Expert Opin Emerg Drugs 2010; 15: 695-711.
97. Hundt W, Danysz W, Holter SM, Spanagel R. Ethanol and Nmethyl-D-aspartate receptor complex interactions: a detailed drug discrimination study in the rat. Psychopharmacology (Berl) 1998; 135: 44-51.
98. Maurice T, Casalino M, Lacroix M, Romieu P. Involvement of the sigma 1 receptor in the motivational effects of ethanol in mice. Pharmacol Biochem Behav 2003; 74: 869-76.
99. Meunier J, Demeilliers B, Celerier A, Maurice T. Compensatory effect by sigma1 (σ1) receptor stimulation during alcohol withdrawal in mice performing an object recognition task. Behav Brain Res 2006; 166: 166-76.
100. Su TP, Hayashi T, Vaupel DB. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci Signal 2009; 2: pe12.
101. Sabino V, Cottone P, Zhao Y, et al. The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology 2009; 34: 1482-93.
102. Sabino V, Cottone P, Blasio A, et al. Activation of sigma-receptors induces binge-like drinking in sardinian alcohol-preferring rats. Neuropsychopharmacology 2011; 36: 1207-18.
103. Sabino V, Cottone P, Zhao Y, Steardo L, Koob GF, Zorrilla EP. Selective reduction of alcohol drinking in Sardinian alcoholpreferring rats by a sigma-1 receptor antagonist. Psychopharmacology (Berl) 2009; 205: 327-35.
104. Wrobel M. Acquisition and expression of ethanol-induced conditioned place preference in mice is inhibited by naloxone. Pharmacol Rep 2011; 63: 79-85.
105. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993; 621: 137-40.
106. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 1997; 129: 99-111.
107. Jarjour S, Bai L, Gianoulakis C. Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcohol Clin Exp Res 2009; 33: 1033-43.
108. Matthews DB. Adolescence and alcohol: recent advances in understanding the impact of alcohol use during a critical developmental window. Alcohol 2010; 44: 1-2.
109. Nagel BJ, Schweinsburg AD, Phan V, Tapert SF. Reduced hippocampal volume among adolescents with alcohol use disorders without psychiatric comorbidity. Psychiatry Res 2005; 139: 181-90.
110. O'Dell LE, Roberts AJ, Smith RT, Koob GF. Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. Alcohol Clin Exp Res 2004; 28: 1676-82.
111. Sabeti J, Gruol DL. Emergence of NMDAR-independent long-term potentiation at hippocampal CA1 synapses following early adolescent exposure to chronic intermittent ethanol: role for sigmareceptors. Hippocampus 2008; 18: 148-68.
112. Tapert SF, Granholm E, Leedy NG, Brown SA. Substance use and withdrawal: neuropsychological functioning over 8 years in youth. J Int Neuropsychol Soc 2002; 8: 873-83.
113. Sabeti J. Ethanol exposure in early adolescence inhibits intrinsic neuronal plasticity via sigma-1 receptor activation in hippocampal CA1 neurons. Alcohol Clin Exp Res 2011; 35: 885-904.
114. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010; 70: 2357-72.
115. Adhikari B, Kahende J, Malarcher A, Pechacek T, Tong V. Smoking-attributable mortality, years of potential life lost, and productivity losses--United States 2000-2004. CDC Morb Mortal Wkly Rep 2008; 57: 1226-8.
116. Hughes JR, Keely J, Naud S. Shape of the relapse curve and longterm abstinence among untreated smokers. Addiction 2004; 99: 29-38.
117. Matsumoto RR, Bowen W, Su TP. Sigma Receptors: Chemistry, Cell Biology and Clinical Implications. New York: Springer Science + Business Media, LLC 2007.
118. Horan B, Gardner EL, Dewey SL, Brodie JD, Ashby CR, Jr. The selective sigma(1) receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (-)-nicotine in rats. Eur J Pharmacol 2001; 426: R1-2.
119. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 1996; 306: 271-9.
120. Paul IA, Basile AS, Rojas E, et al. Sigma receptors modulate nicotinic receptor function in adrenal chromaffin cells. FASEB J 1993; 7: 1171-8.
121. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003; 54: 800-5.
122. Terry P, Katz JL. Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology (Berl) 1997; 134: 201-12.
123. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288: 88-92.
124. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321-7.
125. Gundlach AL, Largent BL, Snyder SH. Characterization of phencyclidine and sigma receptor-binding sites in brain. NIDA Res Monogr 1986; 64: 1-13.
126. Itzhak Y, Ali SF. Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain. Ann N Y Acad Sci 1998; 844: 245-51.
127. NIDA Hallucinogens Infofacts. Bethesda, MD: NIDA; [revised 06/2009; cited 10/22/2011]. Available from: http://drugabuse.gov/infofacts/hallucinogens.html.
128. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 2005; 5: 101-6.
129. Su TP, Wu XZ. Guinea pig vas deferens contains sigma but not phencyclidine receptors. Neurosci Lett 1990; 108: 341-5.
130. Kunitachi S, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 2009; 1279: 189-96.
131. Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007; 32: 514-21.
132. Ishima T, Fujita Y, Kohno M, et al. Improvement of phencyclidine induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clin Chem J 2009; 2: 7-11.
133. Skuza G, Rogoz Z. Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity. Pharmacol Rep 2006; 58: 626-35.
134. Takahashi S, Horikomi K, Kato T. MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. Eur J Pharmacol 2001; 427: 211-9.
135. Holtzman SG. Opioid-and phencyclidine-like discriminative effects of ditolylguanidine, a selective sigma ligand. J Pharmacol Exp Ther 1989; 248: 1054-62.
136. Hondo H, Yonezawa Y, Nakahara T, et al. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res 1994; 633: 337-42.
137. McCullough LD, Salamone JD. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res 1992; 577: 1-9.
138. Steinpreis RE, Salamone JD. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Brain Res 1993; 612: 263-70.
139. Marek P, Chapman CD, Howard S. The effect of phencyclidine and DL-2-amino-5-phosphonovaleric acid on N-methyl-D-aspartic acid induced changes in extracellular concentration of dopamine and DOPAC in the rat neostriatum. Neuropharmacology 1992; 31: 123-7.
140. Yonezawa Y, Kuroki T, Tashiro N, Hondo H, Uchimura H. Potentiation of phencyclidine-induced dopamine release in the rat striatum by the blockade of dopamine D2 receptor. Eur J Pharmacol 1995; 285: 305-8.
141. Millan MJ, Brocco M, Gobert A, et al. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 1999; 11: 4419-32.
142. Ault DT, Werling LL. Phencyclidine and dizocilpine modulate dopamine release from rat nucleus accumbens via sigma receptors. Eur J Pharmacol 1999; 386: 145-53.
143. Bouchard P, Quirion R. [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 1997; 76: 467-77.
144. Soby KK, Mikkelsen JD, Meier E, Thomsen C. Lu 28-179 labels a sigma(2)-site in rat and human brain. Neuropharmacology 2002; 43: 95-100.
145. Chien CC, Pasternak GW. Functional antagonism of morphine analgesia by (+)-pentazocine: evidence for an anti-opioid sigma 1 system. Eur J Pharmacol 1993; 250: R7-8.
146. Chien CC, Pasternak GW. Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther 1994; 271: 1583-90.
147. Chien CC, Pasternak GW. (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol 1995; 294: 303-8.
148. Mei J, Pasternak GW. Sigma1 receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther 2002; 300: 1070-4.
149. Ronsisvalle G, Prezzavento O, Marrazzo A, et al. Synthesis and binding affinity of cis-(-)-and cis-(+)-N-ethyleneamino-Nnordeoxymetazocine and cis-(-)-N-normetazocine analogues at sigma1, sigma2 and kappa opioid receptors. Eur J Pharm Sci 2001; 12: 277-84.
150. Chien CC, Pasternak GW. Sigma antagonists potentiate opioid analgesia in rats. Neurosci Lett 1995; 190: 137-9.
151. Marrazzo A, Prezzavento O, Pappalardo MS, et al. Synthesis of (+)-and (-)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for sigma1 and sigma2 binding sites. Farmaco 2002; 57: 45-53.
152. Kitaichi K, Chabot JG, Moebius FF, Flandorfer A, Glossmann H, Quirion R. Expression of the purported sigma(1) (σ(1)) receptor in the mammalian brain and its possible relevance in deficits induced by antagonism of the NMDA receptor complex as revealed using an antisense strategy. J Chem Neuroanat 2000; 20: 375-87.
153. Wu HE, Schwasinger ET, Terashvili M, Tseng LF. dextro-Morphine attenuates the morphine-produced conditioned place preference via the sigma(1) receptor activation in the rat. Eur J Pharmacol 2007; 562: 221-6.
154. Shin EJ, Nah SY, Chae JS, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats. Neurochem Int 2007; 50: 791-9.
155. Chen SL, Hsu KY, Huang EY, Lu RB, Tao PL. Low doses of dextromethorphan attenuate morphine-induced rewarding via the sigma-1 receptor at ventral tegmental area in rats. Drug Alcohol Depend 2011; 117: 164-9.
156. Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002; 23: 151-6.
157. Sarkar S, Schmued L. Neurotoxicity of ecstasy (MDMA): an overview. Curr Pharm Biotechnol 2010; 11: 460-9.
158. Brammer MK, Gilmore DL, Matsumoto RR. Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors. Eur J Pharmacol 2006; 553: 141-5.
159. Axelrod J. Enzymatic formation of psychotomimetic metabolites from normally occurring compounds. Science 1961; 134: 343.
160. Saavedra JM, Axelrod J. Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science 1972; 175: 1365-6.
161. Berger SP, Hall S, Mickalian JD, et al. Haloperidol antagonism of cue-elicited cocaine craving. Lancet 1996; 347: 504-8.
162. Doody RS. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 1999; 45 Suppl 1: 23-32.
163. Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT. Interaction with sigma(1) protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 2006; 317: 606-14.
164. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005; 100 Suppl 1: 68-77.
165. Grasing K, Mathur D, Newton TF, DeSouza C. Donepezil treatment and the subjective effects of intravenous cocaine in dependent individuals. Drug Alcohol Depend 2010; 107: 69-75.
166. Shoptaw S, Majewska MD, Wilkins J, Twitchell G, Yang X, Ling W. Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study. Exp Clin Psychopharmacol 2004; 12: 126-35.
167. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J Addict Dis 2008; 27: 13-23.
168. Shoptaw S, Huber A, Peck J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006; 85: 12-8.
169. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008; 96: 222-32.
170. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010; 105: 38-48.
171. Jovanovski D, Zakzanis KK. Donepezil in a chronic drug user--a potential treatment? Hum Psychopharmacol 2003; 18: 561-4.
172. Kuehn BM. Nicotine, donepezil may dampen meth craving. JAMA 2006; 296: 31.
173. Farren CK, Scimeca M, Wu R, Malley SO. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend 2009; 99: 317-21.
174. Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167: 668-75.
175. Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants. J Pharmacol Exp Ther 2002; 303: 1227-37.
176. Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008; 3: e2558. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0002558.
177. Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol Disord Drug Targets 2009; 8: 470-4.
178. Chick J, Aschauer H, Hornik K. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 2004; 74: 61-70.
179. Kim KY, Ke V, Adkins LM. Donepezil for alcohol-related dementia: a case report. Pharmacotherapy 2004; 24: 419-21.
180. Marinho V, Laks J, Engelhardt E, Conn D. Alcohol abuse in an elderly woman taking donepezil for Alzheimer disease. J Clin Psychopharmacol 2006; 26: 683-5.
181. Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther 2010; 332: 388-97.